4//SEC Filing
TANG KEVIN 4
Accession 0001415889-24-028661
CIK 0001600620other
Filed
Dec 8, 7:00 PM ET
Accepted
Dec 9, 4:52 PM ET
Size
9.0 KB
Accession
0001415889-24-028661
Insider Transaction Report
Form 4
TANG KEVIN C
Director
Transactions
- Purchase
Common Shares
2024-12-05$8.91/sh+300,000$2,673,000→ 7,529,500 total(indirect: By LP) - Purchase
Common Shares
2024-12-09$9.09/sh+500,000$4,545,000→ 8,429,500 total(indirect: By LP) - Purchase
Common Shares
2024-12-06$9.01/sh+400,000$3,604,000→ 7,929,500 total(indirect: By LP)
Footnotes (4)
- [F1]The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $8.74 to $8.99. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1, 3 and 4.
- [F2]Tang Capital Partners, LP ("TCP") beneficially owns 7,929,500 shares and Tang Capital Partners III, Inc. ("TCP III") beneficially owns 500,000 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Kevin Tang is the sole director and Chief Executive Officer of TCP III, which is indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCP III.
- [F3]These shares were purchased in multiple transactions at prices ranging from $8.89 to $9.15.
- [F4]These shares were purchased in multiple transactions at prices ranging from $8.88 to $9.19.
Documents
Issuer
Aurinia Pharmaceuticals Inc.
CIK 0001600620
Entity typeother
Related Parties
1- filerCIK 0001178579
Filing Metadata
- Form type
- 4
- Filed
- Dec 8, 7:00 PM ET
- Accepted
- Dec 9, 4:52 PM ET
- Size
- 9.0 KB